HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 23, 2013, Pages 9475-9480

  Colin, Philippe ^a,b   Bénureau, Yann ^a   Staropoli, Isabelle ^a   Wang, Yongjin ^a   Gonzalez, Nuria ^c   Alcami, Jose ^c   Hartley, Oliver ^d   Brelot, Anne ^a   Arenzana Seisdedos, Fernando ^a   Lagane, Bernard ^a  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

chemokines; Aids pathogenesis; HIV coreceptor

Indexed keywords

CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120;

ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; ENDOCYTOSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING;

Β CHEMOKINES; AIDS PATHOGENESIS; HIV CORECEPTOR;

CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CHEMOKINES; ENDOCYTOSIS; HIV INFECTIONS; HIV-1; HUMANS; PROTEIN CONFORMATION; RADIOLIGAND ASSAY; RECEPTORS, CCR5; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84878740392     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1222205110     Document Type: Article

References (36)

1. Alkhatib G, et al. (1996) CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272(5270):1955-1958.
2. Blanpain C, et al. (1999) CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 94(6):1899-1905.
3. Mueller A, Mahmoud NG, Strange PG (2006) Diverse signalling by different chemokines through the chemokine receptor CCR5. Biochem Pharmacol 72(6):739-748.
4. Sorce S, Myburgh R, Krause KH (2011) The chemokine receptor CCR5 in the central nervous system. Prog Neurobiol 93(2):297-311.
5. Alkhatib G, Locati M, Kennedy PE, Murphy PM, Berger EA (1997) HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: Independence from G protein signaling and importance of coreceptor downmodulation. Virology 234(2):340-348.
6. Cocchi F, et al. (1995) Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270(5243):1811-1815.
7. Oberlin E, et al. (1996) The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382(6594):833-835.
8. Fantuzzi L, Belardelli F, Gessani S (2003) Monocyte/macrophage-derived CC chemokines and their modulation by HIV-1 and cytokines: A complex network of interactions influencing viral replication and AIDS pathogenesis. J Leukoc Biol 74(5): 719-725.
9. Rosenberg ES, et al. (1997) Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278(5342):1447-1450.
10. Gonzalez E, et al. (2005) The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307(5714):1434-1440.
11. Paxton WA, et al. (1998) Reduced HIV-1 infectability of CD4+ lymphocytes from exposed- uninfected individuals: Association with low expression of CCR5 and high production of beta-chemokines. Virology 244(1):66-73.
12. Zagury D, et al. (1998) C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA 95(7):3857-3861.
13. Barretina J, et al. (2000) Evaluation of the putative role of C-C chemokines as protective factors of HIV-1 infection in seronegative hemophiliacs exposed to contaminated hemoderivatives. Transfusion 40(4):461-467.
14. Nakajima T, Kaur G, Mehra N, Kimura A (2008) HIV-1/AIDS susceptibility and copy number variation in CCL3L1, a gene encoding a natural ligand for HIV-1 co-receptor CCR5. Cytogenet Genome Res 123(1-4):156-160.
15. Gaertner H, et al. (2008) Highly potent HIV inhibition: Engineering a key anti-HIV structure from PSC-RANTES into MIP-1 beta/CCL4. Protein Eng Des Sel 21(2):65-72.
16. Oravecz T, et al. (1997) Regulation of anti-HIV-1 activity of RANTES by heparan sulfate proteoglycans. J Immunol 159(9):4587-4592.
17. Schols D, et al. (1998) CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Res 39(3):175-187.
18. Simmons G, et al. (1997) Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276(5310):276-279.
19. Garcia-Perez J, et al. (2011) New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. J Biol Chem 286(7):4978-4990.
20. Shin N, et al. (2011) Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection. J Pharmacol Exp Ther 338(1):228-239.
21. Doranz BJ, Baik SS, Doms RW (1999) Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events. J Virol 73(12):10346-10358.
22. Gaertner H, et al. (2008) Highly potent, fully recombinant anti-HIV chemokines: Reengineering a low-cost microbicide. Proc Natl Acad Sci USA 105(46):17706-17711.
23. Escola JM, Kuenzi G, Gaertner H, Foti M, Hartley O (2010) CC chemokine receptor 5 (CCR5) desensitization: Cycling receptors accumulate in the trans-Golgi network. J Biol Chem 285(53):41772-41780.
24. Garcia-Perez J, et al. (2011) Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J Biol Chem 286(38):33409-33421.
25. Chabre M, Deterre P, Antonny B (2009) The apparent cooperativity of some GPCRs does not necessarily imply dimerization. Trends Pharmacol Sci 30(4):182-187.
26. Springael JY, et al. (2006) Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. Mol Pharmacol 69(5): 1652-1661.
27. Lagane B, et al. (2005) Mutation of the DRY motif reveals different structural requirements for the CC chemokine receptor 5-mediated signaling and receptor endocytosis. Mol Pharmacol 67(6):1966-1976.
28. Delhaye M, et al. (2007) Identification of a postendocytic sorting sequence in CCR5. Mol Pharmacol 72(6):1497-1507.
29. Berro R, et al. (2011) Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. J Virol 85(16):8227-8240.
30. Amara A, et al. (2003) G protein-dependent CCR5 signaling is not required for efficient infection of primary T lymphocytes and macrophages by R5 human immunodeficiency virus type 1 isolates. J Virol 77(4):2550-2558.
31. Galés C, et al. (2006) Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. Nat Struct Mol Biol 13(9):778-786.
32. Kinter A, Arthos J, Cicala C, Fauci AS (2000) Chemokines, cytokines and HIV: a complex network of interactions that influence HIV pathogenesis. Immunol Rev 177:88-98.
33. Kobilka BK, Deupi X (2007) Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 28(8):397-406.
34. Zidar DA, Violin JD, Whalen EJ, Lefkowitz RJ (2009) Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl Acad Sci USA 106(24):9649-9654.
35. Gurevich VV, Pals-Rylaarsdam R, Benovic JL, Hosey MM, Onorato JJ (1997) Agonistreceptor- arrestin, an alternative ternary complex with high agonist affinity. J Biol Chem 272(46):28849-28852.
36. Choi WT, et al. (2012) CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity. J Virol 86(18):10218-10220.